Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nature’s Sunshine Q1 expectations

This article was originally published in The Tan Sheet

Executive Summary

Net earnings for first quarter ended March 31 expected to be roughly 50% below analysts' estimates, Provo, Utah-based firm announces. Shortfall anticipated even before write-down of a long-term investment that became impaired near the end of the quarter. Although firm would not specify impairment, write-down will be about $3 mil. before tax, $2 mil. after tax. To offset losses, Nature's Sunshine has implemented a company-wide hiring freeze, instituted cost-cutting program. Q1 results expected to reflect 5% drop in U.S. sales, 11% decline in international revenue due to operating losses in Brazil, Japan. Full results are slated for release the week of April 22...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS093886

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel